17,261 trials
Glioblastoma Multiforme · Gliosarcoma · Anaplastic Astrocytoma
Primary: Progression Free Survival at 6 Months — 1.71; 0.89; 8.7; 17.4 percentage of participants
Esophageal Cancer · Gastric Cancer
Primary: Overall Disease-control Rate in Patients With Previously Treated Unresectable or Metastatic Adenocarcinoma of the Upper Gastrointestinal Tract Treated With Everolimus…
Neuroendocrine Carcinoma
Primary: Number of Patients That Experienced a Change in Care Plans After 68GA-DOTATATE PET Scan — 19; 9; 50 participants
Nasal Polyps
Primary: Number of Participants With a Reduced Need for Surgery at Week 25 — 16; 5; 33; 46 Participants — p=0.003
Peritoneal Neoplasms · Ascites · Yang Deficiency
Primary: Objective Response Rate (ORR) — 77.7; 63.8 percentage of participants — p=0.0140
Lymphoma
Primary: Response Rate After 2 Courses of Therapy — 4 participants
Stage I Bladder Cancer · Stage II Bladder Cancer · Stage III Bladder Cancer
Primary: Epigallocatechin Gallate (EGCG) Levels in Nonmalignant Bladder Tissue (e.g., Normal-appearing Urothelium, Inflammatory Lesions in the Bladder, Sessile Noninvasive…
Alzheimer's Disease · Cognitive Impairment
Primary: Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET) — -3.40; -1.07; -7.58; -3.09 SUVBSA2
Myelodysplastic Syndrome · Acute Myeloid Leukemia
Primary: Phase I: Recommended Phase II Dose — 20 mg/day
Soft Tissue Sarcoma
Primary: Progression-free Rate at 12 Weeks (PFR12wks) — 60.0; 31.3 Percentage of participants
Seasonal Affective Disorder
Primary: Structured Interview Guide for the Hamilton Depression Scale - Seasonal Affective Disorder Version (SIGH-SAD); Weekly for Three Weeks — 16.3; 8 units on a scale
Prostate · Cancer · Hormonal Cycling
Primary: Response — 22; 4; 3 participants
Recurrent Bladder Carcinoma · Stage I Bladder Cancer AJCC v6 and v7 · Stage II Bladder Cancer AJCC v6 and v7
Primary: Epidermal Growth Factor Receptor (EGFR) Phosphorylation in Tumor Tissue, as Measured by Immunohistochemistry After the Completion of Treatment — 52.63; 83.33; 93.33…
Acute Disease
Primary: Falls — 0; 2 participants — p=<.05
Huntington Disease
Primary: Ratio of Inorganic Phosphate (Pi) Over Phosphocreatine (PCr): Pi/PCr — 0.44; 0.43; 0.44; 0.42 ratio